Search
Vaxcyte Inc
PCVXAdd to Watchlist
54.080USD
-1.880-3.36%
Close 07-31 16:00（ET）Quotes delayed by 15 min
7.81BMarket Cap
LossP/E TTM
More Details of Vaxcyte Inc Company
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
Vaxcyte Inc Info
Ticker SymbolPCVX
Company nameVaxcyte Inc
IPO dateJun 12, 2020
CEOPickering (Grant E)
Number of employees414
Security typeOrdinary Share
Fiscal year-endJun 12
Address825 Industrial Road, Ste. 300
CitySAN CARLOS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94070
Phone16508370111
Websitehttps://vaxcyte.com/
Ticker SymbolPCVX
IPO dateJun 12, 2020
CEOPickering (Grant E)
Company Executives of Vaxcyte Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
560.66K
-7.93%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
96.84K
--
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
9.44K
+23.99%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
9.44K
+23.99%
Mr. Jacks Lee
Mr. Jacks Lee
Independent Director
Independent Director
3.81K
+59.37%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
2.56K
-392.15%
Mr. John P. Furey
Mr. John P. Furey
Independent Director
Independent Director
2.27K
--
Dr. Olivier Brandicourt
Dr. Olivier Brandicourt
Independent Director
Independent Director
2.19K
--
Mr. James (Jim) Wassil
Mr. James (Jim) Wassil
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
1.63K
-106.51%
Ms. Halley E. Gilbert, J.D.
Ms. Halley E. Gilbert, J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
560.66K
-7.93%
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
President, Chief Financial Officer
President, Chief Financial Officer
96.84K
--
Ms. Teri Loxam
Ms. Teri Loxam
Independent Director
Independent Director
9.44K
+23.99%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
9.44K
+23.99%
Mr. Jacks Lee
Mr. Jacks Lee
Independent Director
Independent Director
3.81K
+59.37%
Mr. Mikhail Eydelman, J.D.
Mr. Mikhail Eydelman, J.D.
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
Senior Vice President, General Counsel, Chief Compliance Officer, Corporate Secretary
2.56K
-392.15%
FAQs
Who are the top five shareholders of Vaxcyte Inc?
The top five shareholders of Vaxcyte Inc are: Mr. Grant E. Pickering
How many institutions hold shares of Vaxcyte Inc (PCVX)?
As of 2026Q1, 718 institutions hold shares of Vaxcyte Inc, with a combined market value of approximately 151.93M, accounting for 105.22% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -5247062.00.